EA202192249A1 - DOSE AND ADMINISTRATION OF C5 ANTIBODIES FOR THE TREATMENT OF MYASTENIA GRAVIS GENERALIZED - Google Patents

DOSE AND ADMINISTRATION OF C5 ANTIBODIES FOR THE TREATMENT OF MYASTENIA GRAVIS GENERALIZED

Info

Publication number
EA202192249A1
EA202192249A1 EA202192249A EA202192249A EA202192249A1 EA 202192249 A1 EA202192249 A1 EA 202192249A1 EA 202192249 A EA202192249 A EA 202192249A EA 202192249 A EA202192249 A EA 202192249A EA 202192249 A1 EA202192249 A1 EA 202192249A1
Authority
EA
Eurasian Patent Office
Prior art keywords
generalized
treatment
antibodies
dose
administration
Prior art date
Application number
EA202192249A
Other languages
Russian (ru)
Inventor
Кенджи Фуджита
Ниши Рампал
Вей-Джиан Пан
Каушик Патра
Original Assignee
Алексион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалс, Инк. filed Critical Алексион Фармасьютикалс, Инк.
Priority claimed from PCT/US2020/018113 external-priority patent/WO2020168079A1/en
Publication of EA202192249A1 publication Critical patent/EA202192249A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Предложены способы клинического лечения генерализованной миастении гравис (gMG) с помощью антитела к C5 или его антигенсвязывающего фрагмента.Methods for the clinical treatment of generalized myasthenia gravis (gMG) using an anti-C5 antibody or an antigen-binding fragment thereof are proposed.

EA202192249A 2019-03-07 2020-02-13 DOSE AND ADMINISTRATION OF C5 ANTIBODIES FOR THE TREATMENT OF MYASTENIA GRAVIS GENERALIZED EA202192249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814935P 2019-03-07 2019-03-07
PCT/US2020/018113 WO2020168079A1 (en) 2019-02-14 2020-02-13 Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Publications (1)

Publication Number Publication Date
EA202192249A1 true EA202192249A1 (en) 2021-12-10

Family

ID=80631193

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192249A EA202192249A1 (en) 2019-03-07 2020-02-13 DOSE AND ADMINISTRATION OF C5 ANTIBODIES FOR THE TREATMENT OF MYASTENIA GRAVIS GENERALIZED

Country Status (1)

Country Link
EA (1) EA202192249A1 (en)

Similar Documents

Publication Publication Date Title
CO2020014773A2 (en) Antibodies to entpd2, combination therapies and methods of use of antibodies and combination therapies
CY1122245T1 (en) PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF
EA202092668A1 (en) ANTIBODIES TO IL-11
EA202092605A1 (en) ANTIBODIES TO IL-11RA
CO2020004831A2 (en) Dosage and administration of anti-c5 antibodies for the treatment of patients with membranoproliferative glomerulonephritis
EA201790339A1 (en) COMBINED DRUGS WITH ANTIBODIES TO CD40
MX2021009789A (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis.
EA202091810A1 (en) ANTIBODIES TO B7-H4 AND METHODS OF THEIR APPLICATION
MX2021008958A (en) Anti-il2 receptor gamma antigen-binding proteins.
JOP20210166A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
MX2021004351A (en) Method for the treatment of myasthenia gravis.
EA202190647A1 (en) ANTIBODIES TO KLRG1
EA202191769A1 (en) TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES
EA202091577A1 (en) GLUCURONYLATION AS A NEW ACID POST-TRANSLATION MODIFICATION OF THERAPEUTIC MONOCLONAL ANTIBODIES
MX2018009264A (en) Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof.
MX2020002750A (en) Il-6r antibody and antigen binding fragment thereof and medical use.
EA201992348A1 (en) ANTIGEN-BINDING PROTEINS INTERACTING WITH JAGGED1
EA202192249A1 (en) DOSE AND ADMINISTRATION OF C5 ANTIBODIES FOR THE TREATMENT OF MYASTENIA GRAVIS GENERALIZED
MX2021008919A (en) Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus).
EA201892244A1 (en) THE MONOVALENT INTERACTION INHIBITOR huTNFR1
MX2022003191A (en) Combination therapy with entpd2 and cd73 antibodies.
BR112022011280A2 (en) ANTI-CD5 ANTIBODY FOR THE TREATMENT OF NEUROMYELITIS OPTIC SPECTRUM DYSFUNCTION
EA202192776A1 (en) DOSING SCHEMES AND COMPOSITIONS INCLUDING ANTIBODIES TO RSV
EA202090894A1 (en) DOSAGE AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
WO2019118906A3 (en) Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein